Get started

PHARMA

Bayer: Down the hatch! 🍺After Bayer's stock recently tried to break through the support level of €39.91, it has now made another attempt. Whether the stock succeeds in sustainably breaking below this support level - as envisaged in our primary scenario - or whether it needs further impetus in the form of a corrective upward move is irrelevant for the further course of our expectations. We therefore fully expect a sell-off below this level, as we expect the low of the major wave (II) correction underway since 2015 to be around the 78.60 retracement at €30.84. Only once this low is in place do we see Bayer shares making sustainable gains again.
XETR:BAYNShort
by MarketIntel
1
Weight loss - Stock GainEli Lilly & Co. is a pharmaceutical company with a long history dating back to its founding by Eli Lilly in May 1876. The company is headquartered in Indianapolis, Indiana, and is engaged in the discovery, development, manufacture, and sale of pharmaceutical products. Their product portfolio includes a range of therapies in various therapeutic areas, such as diabetes, oncology, immunology, neuroscience, and other medical conditions. One notable aspect of their recent success is the introduction of a weight loss drug, tirzepatide. This drug is similar to other medications like Ozempic and Wegovy, which are also designed to help with weight loss. These medications are administered via weekly injections and work by affecting the patient's appetite by mimicking certain hormones in the gut. Wegovy, for instance, primarily mimics the hunger-regulating hormone called GLP-1, while tirzepatide goes a step further by mimicking both GLP-1 and another hormone called GIP. These hormonal effects can lead to decreased appetite, making it easier for individuals to manage their weight.
NYSE:LLYLong
by Helios_Capital_Investment
TEVA SHORT - Israel Palestine ConflictPrice points indicated on chart. Helios is shorting Teva. Looking for put options with close expiry dates. Not financial advice This article explores the potential implications of the ongoing Israel-Palestine conflict, which was initiated on October 7th. Teva, a global pharmaceutical giant, operates five manufacturing facilities situated within a 50-mile radius of the Gaza Strip border. This geographic proximity raises concerns about the company's exposure to heightened geopolitical tensions, as any escalation in the conflict could disrupt, or even lead to the complete shutdown of these facilities. The article also contemplates the likelihood of nations worldwide seeking alternative pharmaceutical suppliers in the event of such disruptions. Teva's Geographic Exposure: Teva Pharmaceutical Industries maintains five manufacturing facilities located within a mere 50 miles of the Gaza Strip border. This close geographic proximity to a region frequently affected by conflicts and geopolitical tensions exposes Teva to a unique set of risks. The facilities in question play a pivotal role in the production and distribution of essential pharmaceutical products, which adds to the significance of this geographical positioning. Potential Consequences: The crux of this article centers on the potential consequences of the Israel-Palestine conflict for Teva Pharmaceuticals. While the conflict's course remains uncertain, any escalation in hostilities could result in a range of adverse outcomes for the company's operations: Factory Closures: In the event of heightened tensions or direct conflict affecting these manufacturing facilities, temporary closures could disrupt production. Such closures might be mandated for employee safety or due to logistical challenges associated with operating in a conflict zone. Shutdown Scenarios: The most extreme scenario involves the complete shutdown of Teva's facilities near the Gaza Strip border. This would not only halt production but also entail significant economic losses for the company. Global Pharmaceutical Market Dynamics: Furthermore, this article contemplates the global pharmaceutical market dynamics in the context of Teva Pharmaceuticals. In the event of disruptions in Teva's supply chain due to the Israel-Palestine conflict, nations worldwide may seek alternative pharmaceutical suppliers to ensure the availability of essential medications. This shift in supplier preferences could impact Teva's market share and revenues. Conclusion: In conclusion, the Israel-Palestine conflict has introduced a unique set of risks and challenges for Teva Pharmaceutical Industries due to its proximity to the conflict zone. While the actual impact remains uncertain and contingent on the course of the conflict, investors and stakeholders should remain vigilant and consider diversification strategies to mitigate geopolitical risks associated with their pharmaceutical investments. The potential ramifications of this conflict extend beyond regional concerns and could reverberate throughout the global pharmaceutical industry, making it imperative for industry observers and investors to closely monitor developments in the region.
NYSE:TEVAShort
by Helios_Capital_Investment
3
Gold before the Fed's decision to raise interest ratesOn the world market, spot gold on Kitco 5/8 traded at 1,942 USD/ounce. Gold price is maintaining at an important resistance level, in the context of the US labor market falling in July, inflationary pressure is still present. ANZ analysts said that the Fed's actions related to the view of adjusting interest rates in the near future could limit gold's rally. Gold is a safe investment asset chosen by many during times of economic uncertainty and geopolitical tension. However, high interest rates negatively affect gold. The key near-term support for gold is around $1,925 an ounce, said Kelvin Wong, senior market analyst at financial brokerage Oanda. If gold falls below this threshold, gold will be able to touch $ 1,895 / ounce.
TVC:GOLD
by SupperTrading-FX
6
ALEMBIC LTD Weekly Double BottomAlembic Ltd has formed a double Bottom on weekly chart, Enter with little qty @ CMP and add on dips for the retest. Safe Buyers can wait for retest of the neckline and enter after confirmation. Please give a boost if you like the analysis and follow for more. Any suggestions or advice is humbly welcomed. Disclaimer:I am not a SEBI Registered Analyst, and the views expressed here are solely my own and for educational purposes only. Make sure you consult your Financial advisor before investing, as I won't be responsible for any losses incurred.
NSE:ALEMBICLTDLong
by Kaushik_Karnale
Eye Spy a MultibaggerI was hesitant to publish this chart because the extreme upside it shows will likely be viewed as unrealistic. However, HROW recently decisively broke above its 4-year trend channel as business developments have been quite positive lately - particularly with IHEEZO. This is a rare setup where the fundamentals and technicals both align for a sharp move to the upside. Over the short-term HROW may retest the trend channel breakout around the $17 region. If it holds, which I expect, I believe we could reach a triple-digit share price in short-order, potentially within 18-months, which would be a 500%+ return from today's share price of $19.50. My personal price target is $150/share by end of year 2025.
NASDAQ:HROWLong
by TomDaSpankEngine
2
Axsome Therapeutics building momentum Axsome Therapeutics Inc (AXSM) I have been in this spot trade since $50.77. We are now at $72.93. I have much higher targets as you can see from the chart. This is a long term trade looking to hold for 12 – 24 months however feel that something is going to happen within 6 – 12 months based on the chart. - Forming pennant on chart and RSI. Potential for breakout. - Steadily increasing OBV (On Balance Volume) demonstrating continued interested in the trade. - Stochastic Momentum indicator (not included on chart is driving upwards on the weekly). - You can see the orange boxes which act as accumulation zones with double bottoms before the larger move occurs. - We are above the 200 week and using it as support and we are above the 200 day also using it as support so we have limited downside with strong support. This purchase has been helped me recognized that Pharma appear to companies perform much better when the general market is in decline. They appear to be inverse risk on but also make small advances during risk on periods. It’s a market that I am becoming increasingly interested in as a diversifier and value lock. Obviously this is a smaller pharma company with higher risk in the trade, however if I was Regeneron or Johnson and Johnson and I see Axsome’s patents, drug offerings and the general population they are targeting with depression, Alzheimer’s and fibromyalgia, seems like a no brainer to buy them out. Fundamentals: AXSM are a Small Bio-Pharma company with market cap of $3.17 Billon. In August 2022 Auvelity Anti-Depressants was FDA approved & is the only rapid-acting oral medicine for MDD with labelling describing statistically significant antidepressant efficacy by one week. AXSM received Breakthrough Therapy designation from the FDA for an Alzheimer's disease drug development and are at the NDA phase for developing a drug for acute treatment of migraine. AXSM are also developing a treatment for narcolepsy and separately for fibromyalgia. All in, AXSM's offerings are building momentum. They have developed the fastest acting anti-depressant drug and are bringing it to market, and have a four other drugs in development, all of which have a large patient base. The company would be ripe for a buyout.
NASDAQ:AXSMLong
by PukaCharts
Mersana Therapeutics: Enjoy!If it holds support, it'll take off and head towards the top end of the range. Check out the crazy Call Options volume for the 8/18 $7.5 Strike Price... over 23,000 for this little unknown Pharma company. Somebody knows something... don't you think? Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of antibody-drug conjugates that offer clinical benefit for cancer patients. Its product candidates are Upifitamab Rilsodotin (UpRi), XMT-1536, and XMT-1592. The company was founded by Mikhail Papisov in 2001 and is headquartered in Cambridge, MA. The listed name for MRSN is Mersana Therapeutics, Inc. Common Stock.
NASDAQ:MRSNLong
by Goontata84
Olema Pharmaceuticals: Enjoy!Olema is currently developing a "cancer" drug that suppresses the body's production of Estrogen. Now this could be useful for breast cancer treatment but the real target audience, in my opinion, is hormone replacement therapy for gender transition. I don't necessarily endorse this kind of product but given the corporate and governmental policies surrounding the issue, I believe it could definitely be a very good financial opportunity. I charted this about a month ago and it has moved even more aggressively than I expected. This could be because this type of product, I imagine, would have to be developed under the current administration. Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of targeted therapies for women's cancers. It also focuses on developing therapies for the treatment of breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA. The listed name for OLMA is Olema Pharmaceuticals, Inc. Common Stock
NASDAQ:OLMALong
by Goontata84
MGRX Biotechonolgy IPO LONGMGRX a recent IPO produces a med for erectile dysfunction without FDA approval; They are basically selling a generic version of an approved medication and bypassing the patent protections and betting they will fly under the regulator radar apparatus. As might be expeted this recent nano-IPO is highlly volatile. Play with it only if you have the requisite skills to do so and only with risk capital. it does the marketing through direct to consumer telehealth services. >>>>>>>>>>>>>>>>>>See also the link below <<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<< On review and analysis on the 30 minute chart, the price action is squeezing down in a flat bottom triangle likely setting up a breakout upside. The RSI oscillator shows RSI crossing 50% from below. Volatility is compressing down inside the triangle for a squeeze set up. Targets are based on the supply and demand zones of the Luxalgo indicator. The first parget is the midline between the zones while the final target is just below the supply zone. As can be seen on the chart, the first target is about 100% upside while the final target is 200% upside. One of the position is closed at each target making the return 150% overall. Stop loss is below the demand zone. A stop loss is 15% yields an overall reward to risk ration of 10:1.
NASDAQ:MGRXLong
by AwesomeAvani